Clinical Trial: A Study to Determine the Effect of KP-001 on Rosuvastatin and Caffeine Pharmacokinetics and the Effect of Fluvoxamine on KP-001 Pharmacokinetics in Healthy Adult Participants

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06821698) titled 'A Study to Determine the Effect of KP-001 on Rosuvastatin and Caffeine Pharmacokinetics and the Effect of Fluvoxamine on KP-001 Pharmacokinetics in Healthy Adult Participants' on Feb. 06.

Brief Summary: Part 1 will evaluate the effects of KP-001 as an inhibitor of BCRP on the PK of rosuvastatin. In the Treatment Period 1, a single dose of rosuvastatin will be administered. In the Treatment Period 2, KP-001 will be administered once daily for 7 days and a single dose of rosuvastatin will be administered. Blood PK assessments of rosuvastatin will be performed until 48 hours postdose in each Treatment Period. Part 2 will evaluate the e...